Payment overview · 2025
General Payments
$4,965.19
88 reported records · 26 companies
Healthcare provider profile · identity verified
Wail E Asfour, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · MUNSTER, IN · NPI 1720038680
Verified facts
What the public records show
CMS Open Payments records show Wail E Asfour, M.D. received $4,965.19 in general payments during 2025 across 88 reported records.
Medtronic, Inc. accounted for 38.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 46 associated products.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 341 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$1,914.58 | 38.6% | 23 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $870.94 | 17.5% | 7 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $298.99 | 6.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $246.94 | 5.0% | 6 | 2025 |
| Surmodics, Inc. | Unresolved — no canonical attribution shown | $200.27 | 4.0% | 1 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $190.50 | 3.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $186.80 | 3.8% | 18 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $177.75 | 3.6% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $177.46 | 3.6% | 2 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $104.30 | 2.1% | 2 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $70.53 | 1.4% | 2 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $66.83 | 1.4% | 3 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $54.92 | 1.1% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $50.69 | 1.0% | 1 | 2025 |
| ENDOTRONIX, INC. | Unresolved — no canonical attribution shown | $45.16 | 0.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.00 | 0.8% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $38.17 | 0.8% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $37.41 | 0.8% | 2 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $33.85 | 0.7% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $31.77 | 0.6% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $29.96 | 0.6% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $24.60 | 0.5% | 1 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $22.65 | 0.5% | 1 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $19.87 | 0.4% | 1 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $16.58 | 0.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.67 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,142.99 | 82 |
| Consulting Fee | $1,125.00 | 1 |
| Travel and Lodging | $646.51 | 4 |
| Long term medical supply or device loan | $50.69 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $1,737.03 | 15 | 2025 |
Source payment records
|
|||||
| IGT Devices Undivided Normalized: igt devices undivided |
Device | Philips North America LLC | $646.51 | 4 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $298.99 | 1 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $298.99 | 1 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy Normalized: pounce thrombectomy |
Device | Surmodics, Inc. | $200.27 | 1 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy System Normalized: pounce thrombectomy system |
Device | Surmodics, Inc. | $200.27 | 1 | 2025 |
Source payment records
|
|||||
| Pounce Venous Thrombectomy System Normalized: pounce venous thrombectomy system |
Device | Surmodics, Inc. | $200.27 | 1 | 2025 |
Source payment records
|
|||||
| Sublime 014 Rx PTA Balloon Dilatation Catheter Normalized: sublime 014 rx pta balloon dilatation catheter |
Device | Surmodics, Inc. | $200.27 | 1 | 2025 |
Source payment records
|
|||||
| Sublime Microcatheter, 018, 200cm, Straight Normalized: sublime microcatheter 018 200cm straight |
Device | Surmodics, Inc. | $200.27 | 1 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $190.50 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $186.80 | 18 | 2025 |
Source payment records
|
|||||
| TURNPIKE Normalized: turnpike |
Device | Teleflex LLC | $163.19 | 1 | 2025 |
Source payment records
|
|||||
| IV Other Normalized: iv other |
Device | Philips North America LLC | $158.07 | 2 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $152.29 | 5 | 2025 |
Source payment records
|
|||||
| EkoSonic Normalized: ekosonic |
Device | Boston Scientific Corporation | $143.46 | 1 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL VENOUS Normalized: mynx control venous |
Device | CORDIS US CORP. | $104.30 | 2 | 2025 |
Source payment records
|
|||||
| XACT Normalized: xact |
Device | Abbott Laboratories | $94.65 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $70.53 | 2 | 2025 |
Source payment records
|
|||||
| DS Zenition 70 Normalized: ds zenition 70 |
Device | Philips North America LLC | $66.36 | 1 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $57.81 | 4 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $54.92 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - ELI 280 Normalized: hillrom eli 280 |
Device | Baxter Healthcare | $50.69 | 1 | 2025 |
Source payment records
|
|||||
| CORDELLA PULOMONARY ARTERY PRESSURE SENSOR Normalized: cordella pulomonary artery pressure sensor |
Device | ENDOTRONIX, INC. | $45.16 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $38.17 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $37.41 | 2 | 2025 |
Source payment records
|
|||||
| COBALT DR MRI SURESCAN Normalized: cobalt dr mri surescan |
Device | Medtronic, Inc. | $34.98 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $34.00 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $33.85 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $33.85 | 1 | 2025 |
Source payment records
|
|||||
| Venovo Normalized: venovo |
Device | Bard Peripheral Vascular, Inc. | $31.77 | 1 | 2025 |
Source payment records
|
|||||
| CLEVIPREX Normalized: cleviprex |
Drug | Chiesi USA, Inc. | $29.96 | 2 | 2025 |
Source payment records
|
|||||
| KENGREAL Normalized: kengreal |
Drug | Chiesi USA, Inc. | $29.96 | 2 | 2025 |
Source payment records
|
|||||
| OPTOWIRE Normalized: optowire |
Device | CARDIVA MEDICAL, INC. | $29.21 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $24.60 | 1 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $22.65 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.96 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.96 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| SAVVYWIRE Normalized: savvywire |
Device | CARDIVA MEDICAL, INC. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| Passeo-18 Normalized: passeo 18 |
Device | BIOTRONIK INC. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| Pulsar-18 T3 Normalized: pulsar 18 t3 |
Device | BIOTRONIK INC. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| GUIDELINER Normalized: guideliner |
Device | Teleflex LLC | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $13.67 | 1 | 2025 |
Source payment records
|
|||||
| AZURE XT DR MRI SURESCAN Normalized: azure xt dr mri surescan |
Device | Medtronic, Inc. | $5.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
341 | 79 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
150 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 646 | 193 |
| Atorvastatin Calcium | Atorvastatin Calcium | 455 | 144 |
| Eliquis | Apixaban | 341 | 79 |
| Metoprolol Tartrate | Metoprolol Tartrate | 285 | 80 |
| Furosemide | Furosemide | 277 | 93 |
| Metoprolol Succinate | Metoprolol Succinate | 231 | 72 |
| Lisinopril | Lisinopril | 213 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 211 | 65 |
| Entresto | Sacubitril/Valsartan | 150 | 35 |
| Amiodarone Hcl | Amiodarone Hcl | 144 | 44 |
| Carvedilol | Carvedilol | 130 | 44 |
| Xarelto | Rivaroxaban | 128 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 118 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 109 | 33 |
| Warfarin Sodium | Warfarin Sodium | 107 | 33 |
| Potassium Chloride | Potassium Chloride | 89 | 37 |
| Alprazolam | Alprazolam | 85 | 21 |
| Losartan Potassium | Losartan Potassium | 77 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 26 |
| Sotalol | Sotalol Hcl | 71 | 21 |
| Simvastatin | Simvastatin | 68 | 22 |
| Levothyroxine Sodium | Levothyroxine Sodium | 66 | 19 |
| Metformin Hcl | Metformin Hcl | 64 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 58 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 19 |
| Digoxin | Digoxin | 49 | 13 |
| Spironolactone | Spironolactone | 47 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 42 | 12 |
| Gabapentin | Gabapentin | 37 | suppressed |
| Allopurinol | Allopurinol | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Famotidine | Famotidine | 29 | suppressed |
| Omeprazole | Omeprazole | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 20 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Jantoven | Warfarin Sodium | 19 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | 13 |
| Finasteride | Finasteride | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 12 |
| Lovastatin | Lovastatin | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Sotalol Af | Sotalol Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,965.19 · 88 records | Medtronic, Inc. | ABRE, AURYON LASER SYSTEM 100-120 VAC, AZURE XT DR MRI SURESCAN, Assure WCD, CAMZYOS, CARDIVA VASCADE MVP VVCS 6-12F, CLEVIPREX, COBALT DR MRI SURESCAN, CORDELLA PULOMONARY ARTERY PRESSURE SENSOR, DS Zenition 70, ENDOCROSS Device, ESPRIT, EkoSonic, FFRct, Flexitouch Plus, GUIDELINER, HAWKONE, Hillrom - ELI 280, IGT Devices Undivided, IV Other, KENGREAL, LEQVIO, LOREEV XR, LifeVest, MYNX CONTROL VENOUS, Nimbl, ONPATTRO, OPTOWIRE, Ozempic, Passeo-18, Pounce Thrombectomy, Pounce Thrombectomy System, Pounce Venous Thrombectomy System, Pulsar-18 T3, Rybelsus, SAVVYWIRE, SYMPHONY CATHETER, Sublime 014 Rx PTA Balloon Dilatation Catheter, Sublime Microcatheter, 018, 200cm, Straight, TURNPIKE, Torus Stent Graft System, VERQUVO, Venovo, WATCHMAN FLX, Wegovy, XACT | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error